Lantern Pharma Inc (LTRN) Stock Price, Quote & News

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central ner...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 277 1136

Website: www.lanternpharma.com

Address:

1920 McKinney Avenue, 7th Floor, Dallas, United States

BabetteCH Aug. 19 at 3:53 PM

$LTRN every day a new (closing-) low. Nice job Panna…

0 · Reply

SevenPhigs27 Aug. 18 at 6:47 PM

$LTRN Added. GLTA

0 · Reply

AtariLynx Aug. 18 at 3:42 PM

$LTRN could reach above 3 in a few seconds. It’s a shame to see it so low. LET’S GO LANTERN PHARMA!

0 · Reply

BabetteCH Aug. 18 at 3:02 PM

$LTRN The new large institutional investors must be absolutely thrilled with this miserable share price performance.

0 · Reply

StocktwitsNews Aug. 14 at 5:45 PM

LTRN Q2 2026 Earnings Summary $LTRN https://stocktwits.com/news/earnings/ai summaries/ltrn-q2-2026-earnings-summary/cZotYIERJ0q

0 · Reply

BabetteCH Aug. 14 at 4:16 PM

$LTRN Today’s Webcast Was Worth Listening To A few key takeaways from today’s earnings webcast: LP-300: Management confirmed “active partnering discussions.” Open Medicine AI: Management believes OMAI could grow to “several hundred million dollars in standalone value.” Big Pharma: Sharma was clear: “Large pharma is definitely interested.” Some have already had multiple calls with the company, with some even visiting. These details go well beyond what you get from simply reading the earnings release. Listen to the transcript/webcast. There’s a lot more between the lines.

3 · Reply